Previous 10 | Next 10 |
The FUROSCIX NDA resubmission is expected to occur during 4Q21. Continued data releases demonstrate the cost-reducing value proposition of FUROSCIX. The liquidity position is very favorable. For further details see: scPharmaceuticals: We Still See A High Probability Of S...
Received minutes from Type C meeting with the FDA confirming alignment on path toward resubmission of FUROSCIX ® NDA; no additional clinical data or device modifications required at this time; on track for resubmission in Q4 Announced positive top-line results from the ...
scPharmaceuticals (SCPH) has added ~8.7% in the post-market after the company announced positive top-line results from its FREEDOM-HF study that was designed to evaluate the effect of FUROSCIX on heart failure-related costs in patients with chronic heart failure.The study has b...
Reduced average 30-day heart failure related costs by $17,753 (p<0.0001) per study subject in FUROSCIX ® arm compared to historically matched comparators Study halted early due to highly statistically significant reduction in 30-day heart failure-related costs observ...
Gainers: Alterity Therapeutics Limited (ATHE) +68%.TRxADE HEALTH (MEDS) +57%.Marin Software (MRIN) +45%.Bridgeline Digital (BLIN) +35%.Birks (BGI) +25%.Pulse Biosciences (PLSE) +25%.SGOCO Group (SGOC) +22%.Grid Dynamics Holdings (GDYN) +19%.scPharmaceuticals (SCPH) +18%.U.S. Silica Holdi...
FDA and Company in alignment on the path forward No additional clinical data or device modifications required at this time FUROSCIX NDA resubmission targeted for Q4 2021 BURLINGTON, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a p...
BURLINGTON, Mass., May 19, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, to...
scPharmaceuticals (SCPH) received a second Complete Response Letter (CRL) on Furoscix rather than an FDA approval in December of 2020. The issues in the CRL are being addressed. The subcutaneous, home delivery of tried-and-true drugs offers a convenient and compelling value propositio...
FREEDOM clinical study on track for topline results in Q3 2021 Ended Q1 with cash, cash equivalents, restricted cash and investments of $96.5 million BURLINGTON, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused...
Gainers: [[SEAC]] +30.3%. [[ABCL]] +13.7%. [[VSTM]] +9.7%. [[GIII]] +9.5%. [[RRR]] +8.8%.Losers: [[WVE]] -24.8%. [[SCPH]] -15.4%. [[PCVX]] -12%. [[UPC]] -9.5%. [[TDUP]] -6%. For further details see: VSTM, WVE, ABCL and SCPH among after-hours movers
News, Short Squeeze, Breakout and More Instantly...
scPharmaceuticals Inc. Company Name:
SCPH Stock Symbol:
NASDAQ Market:
scPharmaceuticals Inc. Website:
BURLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today an...
A look at the top 10 most actives in the United States SiNtx Technologies Inc. (SINT) rose 208.7% to $0.1698 on volume of 325,435,783 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 76.7% to $0.5039 on volume of 314,353,673 shares Greenwave Technology Solutions Inc. (GWAV) ros...
Generated 1Q 2024 net FUROSCIX ® revenue of $6.1 million, despite an estimated 10% impact to doses filled resulting from the Change Healthcare cyberattack Ended 1Q 2024 with cash and cash equivalents o f $58.4 million Company to host investor conference call and web...